{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:35:21Z","timestamp":1793954121465,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.027","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T06:13:45Z","timestamp":1611296025000},"page":"1463-1471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population"],"prefix":"10.1016","volume":"39","author":[{"given":"Ruiju","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongzhou","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjian","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.027_b0005","first-page":"1","article-title":"Polio eradication & endgame strategic plan 2013\u20132018","volume":"23","author":"World Health Organization","year":"2013","journal-title":"Glob Polio Erad Initiat Work Draft"},{"key":"10.1016\/j.vaccine.2021.01.027_b0010","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/infdis\/jix185","article-title":"Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the polio endgame","volume":"216","author":"Zipursky","year":"2017","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2021.01.027_b0015","unstructured":"UNICEF. Inactivated Polio Vaccine (IPV): supply update; 2019."},{"key":"10.1016\/j.vaccine.2021.01.027_b0020","unstructured":"World Health Organization. WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use: GAPIII; 2015."},{"key":"10.1016\/j.vaccine.2021.01.027_b0025","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0030","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","volume":"34","author":"Shimizu","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.vaccine.2017.01.034","article-title":"Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010\u20132014","volume":"35","author":"Liu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0040","first-page":"163","article-title":"Progress with inactivated poliovirus vaccines derived from the Sabin strains","volume":"105","author":"Doi","year":"2001","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2021.01.027_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biologicals.2006.02.010","article-title":"Development of inactivated poliovirus vaccine derived from Sabin strains","volume":"34","author":"Simizu","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2021.01.027_b0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00006454-198811000-00003","article-title":"Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey","volume":"7","author":"Murph","year":"1988","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.01.027_b0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0060","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0065","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1080\/21645515.2019.1572410","article-title":"Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains","volume":"15","author":"Tang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.01.027_b0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1473-3099(17)30177-9","volume":"17","author":"Rivera","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0075","series-title":"Statistics in Clinical Vaccine Trials","author":"Nauta","year":"2011"},{"key":"10.1016\/j.vaccine.2021.01.027_b0080","first-page":"72","article-title":"Safety of diphtheria, tetanus and acellular pertussis containing combination vaccines used in Shanghai, 2015\u20132017","volume":"25","author":"Wu","year":"2019","journal-title":"Chin. J. Vaccines Immunoz"},{"key":"10.1016\/j.vaccine.2021.01.027_b0085","first-page":"692","article-title":"Surveillance for adverse events following immunization with diphtheria, tetanus and acellular pertussis combined vaccine in China, 2015\u20132017","volume":"25","author":"Wang","year":"2019","journal-title":"Chin J Vaccines Immunoz"},{"key":"10.1016\/j.vaccine.2021.01.027_b0090","first-page":"958","article-title":"Evaluation of the safety of diphtheria, tetanus and acellular pertussis containing combination vaccines in Chengdu, 2015\u20132019","volume":"54","author":"Li","year":"2020","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"10.1016\/j.vaccine.2021.01.027_b0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vaccine.2018.11.020","article-title":"Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing","volume":"37","author":"Deng","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0105","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/cid\/ciw492","article-title":"Sex-differential non-vaccine-specific immunological effects of diphtheria-tetanus-pertussis and measles vaccination","volume":"63","author":"Noho-Konteh","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cophys.2018.03.010","article-title":"The evolution of greater humoral immunity in females than males: implications for vaccine efficacy","volume":"6","author":"Fink","year":"2018","journal-title":"Curr Opin Physiol"},{"key":"10.1016\/j.vaccine.2021.01.027_b0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.vaccine.2010.10.071","article-title":"Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau","volume":"29","author":"Agergaard","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2019.10.025","article-title":"The effect of maternal antibodies on the cellular immune response after infant vaccination: a review","volume":"38","author":"Orije","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.027_b0125","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1136\/fn.83.1.F24","article-title":"Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth","volume":"83","author":"Linder","year":"2000","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.vaccine.2021.01.027_b0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1096-9071(200104)63:4<305::AID-JMV1006>3.0.CO;2-U","article-title":"Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine","volume":"63","author":"Sormunen","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.01.027_b0135","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/520546","article-title":"Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants","volume":"196","author":"Asturias","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0145","first-page":"7","article-title":"Inluence of maternal antibodies on effectiveness of two kinds of poliovirus vaccines in the Chinese infants","volume":"39","author":"Ying","year":"2011","journal-title":"Prog in Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2021.01.027_b0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.01.027_b0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/infdis\/jiz124","article-title":"Rapid disappearance of poliovirus type 2 (PV2) immunity in young children following withdrawal of oral PV2-containing vaccine in Vietnam","volume":"220","author":"Huyen","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.027_b0160","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/21645515.2019.1572408","article-title":"Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine","volume":"15","author":"Hotta","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.01.027_b0165","first-page":"173","article-title":"Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic","volume":"76","author":"Marine","year":"1962","journal-title":"Am J Hyg"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:47Z","timestamp":1759402367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21000438"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}